Loading clinical trials...

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

A Randomised, Double-blind, Placebo-controlled, Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

NCT01223911•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability and pharmacokinetics (at which rate the drug is eliminated from the body) of NNC 151-0000-0000 in subjects with rheumatoid arthritis (RA).

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•CZ: Age between 18 and 65 years (both inclusive)
•A diagnosis of rheumatoid arthritis of at least three months before entry in trial
•Active rheumatoid arthritis (RA)
•Subjects are on stable doses of methotrexate (up to and including 25 mg/week) for at least 4 weeks before trial drug administration

Exclusion Criteria

•Known or suspected allergy to trial product or related products
•Body mass index (BMI) less than 18.0 or more than 38.0 kg/m2 (inclusive)

Locations (16)

Novo Nordisk Investigational Site

Prague, Czechia

Novo Nordisk Investigational Site

Frederiksberg, Denmark

Novo Nordisk Investigational Site

Silkeborg, Denmark

Novo Nordisk Investigational Site

Budapest, Hungary

Novo Nordisk Investigational Site

Bialystok, Poland

Novo Nordisk Investigational Site

Elblag, Poland

Novo Nordisk Investigational Site

Krakow, Poland

Novo Nordisk Investigational Site

Poznan, Poland

Novo Nordisk Investigational Site

Bacau, Bacău, Romania

Novo Nordisk Investigational Site

Cluj-Napoca, Cluj, Romania

Key Dates

Start Date

January 1, 2011

Primary Completion Date

February 1, 2013

Completion Date

February 1, 2013

Last Updated

February 9, 2017

Enrollment

34

ACTUAL participants

Conditions

InflammationRheumatoid Arthritis

Interventions

NNC 0151-0000-0000

DRUG

placebo

DRUG

Sponsors

Lead Sponsor

Novo Nordisk A/S

Related Studies

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

NCT07484243

Rheumatoid Arthritis (RA)Rheumatoid Arthritis-Associated Interstitial Lung Disease+1 more

RECRUITINGPHASE1

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

NCT06647069

Systemic Lupus Erythematosus (SLE)Rheumatoid Arthritis (RA)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions